New IPO News | Shenzhen Salubris Pharmaceuticals (002294.SZ) has submitted another application to the Hong Kong Stock Exchange.

According to a disclosure by the Hong Kong Stock Exchange on September 3, Shenzhen Salubris Pharmaceuticals Co., Ltd. (stock code: 002294.SZ) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Goldman Sachs, Citigroup, and CITIC Securities as its joint sponsors. The company had previously submitted an application to the Hong Kong Stock Exchange on February 12. According to the prospectus, Shenzhen Salubris Pharmaceuticals is a leading pharmaceutical company in China focused on the treatment of cardiovascular-renal-metabolic (cardiovascular-renal-metabolic syndrome) diseases, primarily engaged in the research and development, production, and sale of drugs and medical devices. According to Frost & Sullivan, the company ranks second in terms of hospital sales revenue of cardiovascular drugs in China, with a market share of 11.3% by 2025.